Neoadjuvant immunotherapy

Immunotherapy has revolutionized cancer treatment, however only a fraction of patients respond to treatment. Administering immunotherapy in the neo-adjuvant, pre-operative setting is an emerging therapeutic option and neoadjuvant immunotherapy–based clinical trials have now been conducted in several cancer types. 

With this Collection, a partnership between Nature, Nature Medicine and Nature Communications, we welcome submissions of primary research papers that focus on neo-adjuvant immunotherapies and related combinatorial approaches (such as radio-immunotherapy or chemo-immunotherapy). Our interest is not limited to studies first reporting primary and secondary outcomes of interventional clinical trials, but we also encourage the submission of post hoc analyses of published neo-adjuvant immunotherapy trials. Associated studies using cancer patient samples, aiming to provide immunological mechanistic insights or to develop prognostic biomarkers, are also welcomed.

Please note that the journals follow the recommendations from the International Committee of Medical Journal Editors (ICMJE) and the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network for registration and reporting clinical studies. When preparing your submission, please refer to the shared journal guidelines.

We also remain interested in preclinical studies testing different neoadjuvant immunotherapy approaches. In particular, we encourage submissions of pre-clinical works assessing combinatorial approaches in a neo-adjuvant setting. 

We will highlight relevant papers in this collection, together with neo-adjuvant immunotherapy-related articles recently published by the journals.